These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25708835)

  • 1. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
    Flynn J; Jones J; Johnson AJ; Andritsos L; Maddocks K; Jaglowski S; Hessler J; Grever MR; Im E; Zhou H; Zhu Y; Zhang D; Small K; Bannerji R; Byrd JC
    Leukemia; 2015 Jul; 29(7):1524-9. PubMed ID: 25708835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
    Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
    Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
    Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
    Gojo I; Sadowska M; Walker A; Feldman EJ; Iyer SP; Baer MR; Sausville EA; Lapidus RG; Zhang D; Zhu Y; Jou YM; Poon J; Small K; Bannerji R
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):897-908. PubMed ID: 23949430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
    Kumar SK; LaPlant B; Chng WJ; Zonder J; Callander N; Fonseca R; Fruth B; Roy V; Erlichman C; Stewart AK;
    Blood; 2015 Jan; 125(3):443-8. PubMed ID: 25395429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
    Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
    J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
    Mitri Z; Karakas C; Wei C; Briones B; Simmons H; Ibrahim N; Alvarez R; Murray JL; Keyomarsi K; Moulder S
    Invest New Drugs; 2015 Aug; 33(4):890-4. PubMed ID: 25947565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
    Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
    Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
    Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
    Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
    Johnson AJ; Yeh YY; Smith LL; Wagner AJ; Hessler J; Gupta S; Flynn J; Jones J; Zhang X; Bannerji R; Grever MR; Byrd JC
    Leukemia; 2012 Dec; 26(12):2554-7. PubMed ID: 22791353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; O'Brien S; Flinn IW; Kipps TJ; Weiss M; Rai K; Lin TS; Woodworth J; Wynne D; Reid J; Molina A; Leigh B; Harris S
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4448-55. PubMed ID: 17671129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
    Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
    Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
    Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
    Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
    Mody R; Zhao L; Yanik GA; Opipari V
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.